Analysts foresee more revenue arGEN-X

Tomorrow the Belgian arGEN-X will report its past quarter's results. Over the current book year the total revenue will be 36,8 million euros (consensus estimates). This is slightly more than 2017's revenue of 36,42 million euros.

Historical revenues and results arGEN-X plus estimates 2018

The analysts expect for 2018 a net loss of 54 million euros. The majority of the analysts expects for this year a loss per share of 1,51 euros. Based on this the price/earnings-ratio is -46,23.

Analysts don't expect the company to pay a dividend. The average dividend yield of the biotech companies is a poor 0,5 percent.

arGEN-X's market value equals around 1,4 billion . The arGEN-X stock was the past 12 months quite unstable. Since last October the stock is even 258 percent higher. This year the stock price moved between 19 and 95 euro.

Historical stock prices arGEN-X from 2007 till 2018

ValueSpectrum.com News Wire & Equity Research: +31 084-0032-842
news@valuespectrum.com

Copyright analist.nl B.V.
All rights reserved. Any redistribution, duplication or archiving prohibited. analist.nl doesn't warrant the accuracy of any News Content provided and shall not be liable for any errors, inaccuracies or for any actions taken in reliance thereon.